Nonalcoholic Steatohepatitis Diagnostics Market Size

Nonalcoholic Steatohepatitis Diagnostics Market size was valued at USD 1.52 billion in 2024 and is set to reach USD 24.15 billion by the end of 2037, registering around 23.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of nonalcoholic steatohepatitis diagnostics is assessed at USD 1.81 billion.

The growth of the market can be attributed to the high prevalence rate of NAFLD, including both NAFL and NASH, raises the need for advanced Nonalcoholic Steatohepatitis (NASH) diagnostics techniques. NAFLD, with both NAFL and NASH, is the most common cause of abnormal liver enzymes in the developed nations. The prevalence of NAFLD and NASH in adults in the United States is 30% to 40% and 3% to 12%, respectively, and it has been increasing given the growing prevalence of the predisposing conditions. Most patients with NAFLD and NASH are asymptomatic, and the disease is typically diagnosed incidentally on routine blood work. Because of this, more advanced technologies are in the pipeline to diagnosis the condition due to which the market is accelerating globally.

In addition to these, factors that are believed to fuel the market growth of nonalcoholic steatohepatitis (NASH) diagnostics include the dominant presence of major players and rising product launches for nonalcoholic steatohepatitis (NASH) diagnostics increases the market. For Instance, in 2021, Siemens Healthineers announced that its Enhanced Liver Fibrosis (ELF) Test was approved for marketing authorization under the De Novo review pathway. The ELF Test, for applications with the ADVIA Centaur XP Immunoassay System, offers a simple numeric score that is automatically produced via an algorithm and is used to enhance patient care by assessing the probability of progression to cirrhosis and liver-related clinical events in patients with progressive fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH). Thus, expanding product launches and research activities towards nonalcoholic Steatohepatitis (NASH) diagnostics accelerates the market growth.